Evidence map›Paper›PMID 41929060›Full record

ArticlebioRxiv : the preprint server for biology2026

Early immune responses anticipate HIV rebound and precede viral control.

Anna Farrell-Sherman, Walker Azam, Natalia de la Force, Ellen L White, Demi A Sandel, Antonio E Rodriguez, Tony Figueroa, Thomas Dalhuisen, Meghann C Williams, Viva Tai and 16 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Anna Farrell-ShermanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0009-0004-4736-4546
Walker AzamVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Natalia de la ForceVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Ellen L WhiteVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Demi A SandelDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Antonio E RodriguezDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Tony FigueroaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Thomas DalhuisenDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Meghann C WilliamsDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Viva TaiDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
George W GruenhagenDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Alaa AbdellatifDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Gabriela K FragiadakisDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Peyman SamghabadiDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Carlo De la Sancha VerduzcoDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Poonam VohraDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Cynthia GasperDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Steven LongDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, United States.
Bokai ZhuRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.
Alex K ShalekRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.
Rebecca HohDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Rachel L RutishauserDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Michael J PelusoDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-6371-747X
Lillian B CohnVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$35.7M
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIVR01AI170239 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rachel Lena Rutishauser · 2022 to 2026
$4.0M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Bill & Melinda Gates Foundation INV-002707NCATS NIH HHS UL1 TR001872NCI NIH HHS P30 CA015704NIAID NIH HHS K23 AI157875NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI170239NIAID NIH HHS R24 AI067039NIAID NIH HHS T32 AI007140NIAID NIH HHS U54 AI170792NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164565NIGMS NIH HHS T32 GM136547
6 · The paper itself

Abstract

Sustained viral suppression following antiretroviral treatment (ART) cessation is a major goal of HIV cure research

Identifiers

PMID41929060
PMCPMC13041810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.